This is a revised AITRP proposal for a postgraduate training initiative with an emphasis on HIV/AIDS clinical pharmacology between the University at Buffalo (UB) and the University of Zimbabwe (UZ). The program faculty at both institutions are experienced investigators that will contribute mentored training to UZ students who, in turn, will contribute clinical pharmacology expertise to multidisciplinary teams to achieve the HIV/AIDS research goals for Zimbabwe. The program is designed for AITRP trainees to benefit from mentored interactions with faculty and health professionals with established clinical/translational and laboratory research environments. The AITRP infrastructure has been broadened to include formalized collaboration with NIAID-funded international, multidisciplinary research networks in Zimbabwe, coordinated through the UZ Clinical Trials Site, as well as other US-supported and Zimbabwe-based research programs. This approach will provide opportunities for AITRP trainees to develop their research career during the AITRP and then continue in a collaborative, mentored environment after the training period. This revised application includes a focused didactic curriculum for postgraduate trainees and an integrated research project experience that includes on-site training at UB and UZ. The AITRP will focus on a group of highly trained individuals who will then pursue their research programs within the multidisciplinary environment that is present at UZ with continued mentoring and career development. Strong institutional support for the proposed AITRP is evident through participation of faculty and administrative leaders at UZ in recognition of the need to support the development of future researchers to address the HIV/AIDS epidemic in Zimbabwe.
As the HIV/AIDS epidemic has continued to impact on developing countries, the need for training in HIV/AIDS clinical Pharmacology has also expanded in scope. Our AITRP meets these needs by providing a mechanism for multi-disciplinary training to conduct HIV/AIDS treatment research and achieve the goals that Zimbabwe has established for optimizing antiretroviral therapy and expanding its pool of clinician scientists.
|Makita-Chingombe, Faithful; Kutscher, Hilliard L; DiTursi, Sara L et al. (2016) Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations. J Drug Deliv 2016:3810175|
|Parikh, Sunil; Fehintola, Fatai; Huang, Liusheng et al. (2015) Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. Antimicrob Agents Chemother 59:7852-6|
|Dube, Admire; Reynolds, Jessica L; Law, Wing-Cheung et al. (2014) Multimodal nanoparticles that provide immunomodulation and intracellular drug delivery for infectious diseases. Nanomedicine 10:831-8|
|Scarsi, Kimberly K; Fehintola, Fatai A; Ma, Qing et al. (2014) Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. J Antimicrob Chemother 69:1370-6|
|Oramasionwu, Christine U; Morse, Gene D; Lawson, Kenneth A et al. (2013) Hospitalizations for cardiovascular disease in African Americans and whites with HIV/AIDS. Popul Health Manag 16:201-7|
|Mudzviti, Tinashe; Sibanda, Marvelous; Gavi, Samuel et al. (2012) Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program. J Infect Dev Ctries 6:806-8|
|Mudzviti, Tinashe; Maponga, Charles C; Khoza, Star et al. (2012) The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe. AIDS Res Treat 2012:434171|
|Oramasionwu, Christine U; Koeller, Jim M; Lawson, Kenneth A et al. (2012) The state of disparities in opportunistic infection prophylaxis for blacks with HIV/AIDS. Med Care 50:920-7|
|Morse, Gene D; Maartens, Gary; Maponga, Charles Chiedza et al. (2012) Global HIV/AIDS Clinical and Translational Pharmacology. AIDS Res Treat 2012:973627|
|Fehintola, Fatai A; Scarsi, Kimberly K; Ma, Qing et al. (2012) Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Res Treat 2012:703604|
Showing the most recent 10 out of 12 publications